Alexander Pasternak Laboratory of Experimental Virology, Department of Medical Microbiology Academic Medical Center of the University of Amsterdam Amsterdam,

Slides:



Advertisements
Similar presentations
Transient HAART During PHI Prolongs the Total Time Off HAART in Patients Presenting with PHI: Data from the Dutch Primo-SHM Cohort R. Steingrover, S. Jurriaans,
Advertisements

New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida.
The HDAC inhibitor romidepsin is safe and effectively reverses HIV-1 latency in vivo as measured by standard clinical assays Ole Schmeltz.
Protective HLA Class I alleles are associated with reduced immune activation in Primary HIV infection Elizabeth Hamlyn 1, Stephen Hickling 2, Abdel Babiker.
David M. Margolis, MD Professor of Medicine Towards an HIV cure: medical, social and ethical challenges in research and testing.
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial James Williams 1,2,3, Jacob Hurst 1,2,3,
T-cell activation positively correlates with cell-associated HIV-DNA level in PBMCs in viremic patients with acute or chronic HIV-1 infection Laurence.
Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.
J.L.K. Fletcher, S. Pinyakorn, M. de Souza, S. Akapirat, R. Trichavaroj, T. Pankam, E. Kroon, D. Colby, P. Prueksakaew, D. Suttichom, J.H. Kim, P. Phanuphak,
Autologous T-cell therapy based on a lentiviral vector expressing long antisense RNA targeted against HIV-1 env gene influences HIV replication and evolution.
Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy S. Fourati 1, R. Calin 2, G. Carcelain 3, P.
Immune correlates of unusual control of viral replication after cessation of HAART Ellen Van Gulck 1, Leo Heyndrickx 1, Céline Merlin 1, Sandra Coppens.
Long-term ART initiated during primary HIV-1 infection limits the HIV-1 reservoir size but not to levels found in LTNPs Eva Malatinkova, Ward De Spiegelaere,
Safety and effect of an extract from Ganoderma lucidum (Reishi) on NK cell numbers in HIV+ individuals not taking antiretroviral therapy. JT Leonard 1,
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.
Predicting NNRTI Resistance – do polymorphisms matter? Nicola E Mackie 1, Lucy Garvey 1, Anna Maria Geretti 2, Linda Harrison 3, Peter Tilston 4, Andrew.
Viral Tissue Reservoirs Are Determined Early and Little Viral RNA Is Detected during Suppression in the Macaque Model Zandrea Ambrose, Ph.D. Division of.
Poster # 388 CROI Feb Montreal, Canada Association of HIV-1 Co-receptor Tropism with Immunologic and Virologic Parameters in HIV-1 infected,
Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California,
Is Highly Active Antiretroviral Therapy (HAART) in pregnancy protective against maternal mortality? Results from a large DREAM cohort in Malawi and Mozambique.
The Positive Predictive Value of World Health Organization (WHO) Immunologic Criteria for Treatment Failure in a Public Health Antiretroviral Delivery.
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
Association between CSF and peripheral markers of immune- activation/inflammation and elevated intratechal HIV–RNA levels in a cohort of.
Kuala Lumpur, Malaysia, 30 June - 3 July 2013 In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500.
Functional cure after long term HAART initiated during early HIV infection - a case study. van Lunzen J. 1,2, Schulze zur Wiesch J. 1,2, Schumacher U.
Immune Discordance on Highly Active Antiretroviral Therapy Can Still be Regarded as a Therapeutic Success Nur F. Önen MD, MRCP 1, Rachel Presti MD PhD.
HIV Cellular Pathogenesis III Benhur Lee, M.D.. Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load.
Learning About an HIV Cure by Doing Studies in HIV+ Subjects Alan Landay, PhD Professor and Chairman Department of Immunology/Microbiology Rush University.
Good Three-year Outcomes of Antiretroviral Therapy at Multiple NGO- assisted facilities in Four Provinces in South Africa Geoffrey Fatti, Ashraf Grimwood.
Clinical and mycological determinants of Cryptococcosis-associated IRIS (C-IRIS) Chang CC, Elliott JE, Gosnell BI, Dorasamy AA, Omarjee S, Naranbhai V,
Persistent immune activation despite suppressive HAART is associated with higher risk for viral blips in HIV-1 infected individuals Alexander Zoufaly 1.
What are possible biomarkers for cure-related interventions ? Lars Ostergaard, MD, Ph.D., DMSc Prof/Head Dept of infectious diseases Aarhus.
HIV: Science, Sex and Society. Lecture 1. Mechanisms of viral persistence in the face of antiviral therapy. Mario Stevenson, Ph.D Department of Medicine.
Robert F. Siliciano, MD, PhD Professor of Medicine The Johns Hopkins University School of Medicine Baltimore, Maryland Update on HIV Cure Research FORMATTED:
T-cell activation positively correlates with cell-associated HIV-DNA level in PBMCs in viremic patients with acute or chronic HIV-1 infection Laurence.
Immune reconstitution Anjie Zhen, PhD
Date of download: 5/28/2016 From: Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation: Report of 2 Cases Ann.
Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Influence of the Timing of Antiretroviral Therapy.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
CD4 trajectory among HIV positive patients receiving HAART in a large East African HIV care centre Agnes N. Kiragga 1, Beverly Musick 2 Ronald Bosch, Ann.
Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Antiretroviral Therapy on Viral Load, CD4.
First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.
Kingdome of Saudia Arabia Al-Majmaah University Applied of Medical Science Clinical Virology CLINICAL VIROLOGY MDL 325 Presented by : Mohammad Al- Turaqi.
1 Predictors of virological failure in a Cambodian setting Sokkab An, M.D Sihanouk Hospital Center of HOPE (SHCH), Phnom Penh, Cambodia.
This presentation is intended for educational use only, and does not in any way constitute medical consultation or advice related to any specific patient.
Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.
G. E. Martin. , N. Pantazis. , M. Hoffmann. , S. Hickling, J. Hurst, J
The impact of treatment duration on defective and expanded identical HIV genomes in T cell subsets from peripheral blood and tissues Eunok Lee.
Viral and Host characteristics of a child with perinatal HIV-1 after prolonged period of ART cessation in the CHER trial Avy Violari, Mark Cotton, Louise.
Emory University School of Medicine Department of Medicine
Earlier treatment and lower mortality in infants Initiating ART at
HIV Cure: Current Status and Future Perspectives
Factors affecting virological failure in patients receiving antiretroviral therapy: a prospective HIV Clinical cohort in rural Uganda. Patrick Kazooba1,
Higher rate of antiretroviral therapy reinitiation among HIV-HBV coinfected patients in the episodic arm of the SMART study Dore G.1, Soriano V.2, Neuhaus.
Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.
Feedback meeting September 2017
HIV-1 PLASMA VIRAL LOAD IN TREATMENT NAÏVE HIV-1 PATIENTS
Predictors of antiretroviral treatment associated tuberculosis in Ethiopia: a nested case control study Nebiyu Mesfin, MD.
Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following.
The role of CD4 in patient monitoring Amsterdam July 2018
The block-and-lock approach
HIV-1 specific restriction factors increase in response to viral rebound after analytical treatment interruption De Scheerder Marie-Angélique, Van Hecke.
Monique Nijhuis University Medical Center Utrecht, the Netherlands
Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral.
Residual HIV replication + virus/cell latency + viral sanctuaries
Li Huang Duke University, North Carolina, USA
Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral.
Biomarkers as Endpoints
Share your thoughts on this presentation with #IAS2019
Presentation transcript:

Alexander Pasternak Laboratory of Experimental Virology, Department of Medical Microbiology Academic Medical Center of the University of Amsterdam Amsterdam, The Netherlands Cell-associated HIV-1 unspliced RNA level predicts both time to virological suppression and duration of post-treatment virological control in patients treated with temporary early ART

Cell-associated HIV nucleic acids were quantified in PBMC at PHI and every 12 weeks thereafter during early ART PHI ARTCHI ART PLoS Med, March 2012

Time trends of cell-associated HIV nucleic acids on PHI ART

What determines the rate of virological suppression after ART initiation? Plasma viral load, CD4+ count, CD4/CD8 ratio, unspliced RNA, multiply spliced RNA, and total viral DNA were measured at PHI

p=0.016 p=0.70 p=0.13 p= p=0.83 p=0.16 In the multivariate Cox regression, US RNA at PHI was the only significant predictor of the time to virological suppression (HR=0.65 per 1 log 10 increase in US RNA, 95% CI, , p=0.0043).

Early initiation of ART is one of the most promising strategies for HIV cure Chun Fauci AIDS 2012 For the improved design of strategies towards HIV-1 functional cure, it is important to identify biomarkers that could predict the duration of post-treatment virological control (Visconti study, etc.)

What determines the rate of virological rebound after ART interruption? Unspliced RNA, total viral DNA, and CD4+ count were measured before interruption of early ART

p=0.021 p=0.35 p=0.28 p=0.51 Further exploration of US RNA as a predictor of post-treatment control in large-scale clinical trials aimed at HIV functional cure is warranted

What determines the rate of disease progression (CD4+ T-cell loss) after interruption of early ART? Plasma viral load, CD4+ count, CD4/CD8 ratio, unsplced RNA, multiply spliced RNA, and total viral DNA were measured at the virological setpoint (36 weeks after early ART interruption)

p=0.091p=0.0001p=0.014 p=0.81p=0.0002p=0.44 In the multivariate Cox regression analysis, CD4+ count (p=0.0004) and MS RNA level (p=0.011) were the only two significant predictors of disease progression.

Conclusions Cell-associated HIV-1 unspliced RNA level independently predicted both time to virological suppression and time to virological rebound in patients treated with temporary early ART Cell-associated HIV-1 multiply spliced RNA level independently predicted disease progression (CD4+ T-cell loss) after interruption of early ART, while unspliced RNA was not predictive It looks like reactivation of HIV after therapy is interrupted and subsequent CD4+ T-cell loss are driven by different mechanisms

We might be wrong… HIV DNA: a marker of total reservoir (mostly defective) Unspliced RNA: a marker of active reservoir (cells that produce virus or can become reactivated to do so upon latency reversal) Multiply spliced RNA: a marker of “hyperactive reservoir” (cells with high MS RNA levels, a subset of active reservoir – the relative size of this “hyperactive reservoir” may drive HIV pathogenesis, determining the rate of CD4 T-cell loss) Total (DNA +) Active (DNA + US-RNA + ) Hyperactive (DNA + US-RNA + MS-RNA high )

Acknowledgements Margreet Bakker Suzanne Jurriaans Ben Berkhout Medical Microbiology, AMC Marlous Grijsen Jan Prins Infectious Diseases, Tropical Medicine and AIDS, AMC This study was supported by the research grant from the Dutch AIDS Fonds

Does any parameter predict normalization of CD4/CD8 ratio (>1) on early ART?

CD4/CD8 48w <1CD4/CD8 48w >1CD4/CD8 48w <1CD4/CD8 48w >1CD4/CD8 48w <1CD4/CD8 48w >1 CD4/CD8 48w <1CD4/CD8 48w >1CD4/CD8 48w <1CD4/CD8 48w >1CD4/CD8 48w <1CD4/CD8 48w >1 p=0.075 p=0.095 p=0.058 p=0.44 p= p=0.22 MS RNA was the only significant predictor of CD4:CD8 ratio normalization in multivariate logistic regression (p=0.015)